Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
IRIS International, Inc.
IRIS International Receives Institutional Review Board Approval to Begin the First Stage of Its Clinical Study Using NADiA™ ProsVue™ for Identifying Post-Prostatectomy Patients with Low Risk of Prostate Cancer Recurrence
January 27th, 2009
IRIS INTERNATIONAL, INC. (NASDAQ: IRIS), announced that it has received Institutional Review Board (IRB) approval from Duke University Medical Center to immediately begin a retrospective clinical study utilizing its NADiA™ ProsVue™ ultra sensitive prostate-specific antigen diagnostic assay. The first stage of the clinical study will use retained serum samples of 30 patients whose prostate cancer relapse, or remission, has been clinically confirmed with imaging data or the patient’s death. The NADiA™ ProsVue™ assay will be independently used in this study to assist the Company in furthering the hypothesis that NADiA™ ProsVue™ can prognosticate patients as low risk of prostate cancer...
Source: Cancer Weekly (2009-01-27)
|
